Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3520LO2W
Performance in the last:
Follow this Portfolio
1D -1.2 %
1W -5.5 %
2W -1.3 %
1M -0.5 %
3M -2.7 %
6M 3.0 %
9M 9.2 %
1Y 21.1 %
Alpha
9.8%
Beta
0.55
sharpe-R
0.97
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.69
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-02-04 07:50:24
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -10.53%
Max. DrawDown Benchmark -8.41%

This Long Only strategy aims to find promising assets to invest in for a maximum holding period of 2 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 20.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
2
Difficulty Level
2

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Asset Class Action Weight PnL
AGEN Agenus Inc. Equity Buy 3.99% -8.36%
BHVN Biohaven Ltd. Equity Buy 4.21% -3.38%
BLFS BioLife Solutions, Inc. Equity Buy 4.89% -5.94%
FATE Fate Therapeutics, Inc. Equity Buy 4.84% -7.3%
SGMO Sangamo Therapeutics, Inc. Equity Buy 4.96% -4.88%
NTRA Natera, Inc. Equity Buy 5.23% 0.16%
RGNX REGENXBIO Inc. Equity Buy 4.88% -3.1%
The percentage of cash held in the portfolio is: 67%
** The description of each asset is available Here

The latest 5 Compositions change

2025-02-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
AGEN Agenus Inc. Buy 3.99% -8.36%
BHVN Biohaven Ltd. Buy 4.21% -3.38%
BLFS BioLife Solutions, Inc. Buy 4.89% -5.94%
FATE Fate Therapeutics, Inc. Buy 4.84% -7.3%
SGMO Sangamo Therapeutics, Inc. Buy 4.96% -4.88%
NTRA Natera, Inc. Buy 5.23% 0.16%
RGNX REGENXBIO Inc. Buy 4.88% -3.1%
The percentage of cash held in the portfolio is: 67%
New Assets Added
None
Assets Removed
Asset Action Perf %
SIGA Sell All -9.55%
Assets Rebalanced
None
2025-02-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
AGEN Agenus Inc. Buy 4.27% -0.78%
BHVN Biohaven Ltd. Buy 4.22% -2%
SIGA SIGA Technologies, Inc. Buy 4.63% -6.42%
BLFS BioLife Solutions, Inc. Buy 4.96% -3.5%
FATE Fate Therapeutics, Inc. Buy 4.89% -5.11%
SGMO Sangamo Therapeutics, Inc. Buy 5.15% 0%
NTRA Natera, Inc. Buy 5.17% 0.37%
RGNX REGENXBIO Inc. Buy 4.98% 0%
The percentage of cash held in the portfolio is: 61.72%
New Assets Added
  • RGNX
Assets Removed
Asset Action Perf %
CPRX Sell All -5.84%
TGTX Sell All -0.69%
SENS Sell All -14.96%
Assets Rebalanced
None
2025-01-31 00:00:00 : Portfolio change date
Asset Action Weight PnL
AGEN Agenus Inc. Buy 3.94% -7.57%
BHVN Biohaven Ltd. Buy 4.25% -0.08%
SIGA SIGA Technologies, Inc. Buy 4.72% -3.6%
SENS Senseonics Holdings, Inc. Buy 4.14% -3.54%
TGTX TG Therapeutics, Inc. Buy 4.78% 4.51%
BLFS BioLife Solutions, Inc. Buy 4.98% -2.12%
CPRX Catalyst Pharmaceuticals, Inc. Buy 4.92% -3.21%
FATE Fate Therapeutics, Inc. Buy 5.1% 0%
SGMO Sangamo Therapeutics, Inc. Buy 5.1% 0%
NTRA Natera, Inc. Buy 5.1% 0%
The percentage of cash held in the portfolio is: 52.98%
New Assets Added
  • FATE
  • SGMO
  • NTRA
Assets Removed
Asset Action Perf %
ORGO Sell All 13.21%
Assets Rebalanced
None
2025-01-30 00:00:00 : Portfolio change date
Asset Action Weight PnL
ORGO Organogenesis Holdings Inc. Buy 5.29% 14.11%
AGEN Agenus Inc. Buy 4.01% -5.74%
BHVN Biohaven Ltd. Buy 4.11% -3.33%
SIGA SIGA Technologies, Inc. Buy 4.79% -2.03%
SENS Senseonics Holdings, Inc. Buy 3.95% -7.96%
TGTX TG Therapeutics, Inc. Buy 4.77% 4.54%
BLFS BioLife Solutions, Inc. Buy 5.08% 0%
CPRX Catalyst Pharmaceuticals, Inc. Buy 5.08% 0%
The percentage of cash held in the portfolio is: 62.93%
New Assets Added
  • BLFS
  • CPRX
Assets Removed
Asset Action Perf %
MD Sell All 1.36%
MDXG Sell All 2.61%
NVRO Sell All 19.34%
LGND Sell All 7.83%
AXSM Sell All 12.15%
CERS Sell All 4.86%
DNLI Sell All 8.88%
ATXS Sell All -4.24%
RGNX Sell All 1.08%
ANIP Sell All 4.95%
Assets Rebalanced
None
2025-01-29 00:00:00 : Portfolio change date
Asset Action Weight PnL
MD Pediatrix Medical Group, Inc. Buy 4.95% 3.29%
MDXG MiMedx Group, Inc. Buy 4.92% 2.72%
NVRO Nevro Corp. Buy 5.64% 17.69%
LGND Ligand Pharmaceuticals Incorporated Buy 5.13% 7.1%
AXSM Axsome Therapeutics, Inc. Buy 5.24% 9.29%
CERS Cerus Corporation Buy 5.49% 14.59%
DNLI Denali Therapeutics Inc. Buy 5.24% 9.3%
ATXS Astria Therapeutics, Inc. Buy 4.61% -3.85%
RGNX REGENXBIO Inc. Buy 4.9% 2.15%
ANIP ANI Pharmaceuticals, Inc. Buy 5.01% 4.54%
ORGO Organogenesis Holdings Inc. Buy 4.94% 6.91%
AGEN Agenus Inc. Buy 3.94% -7.05%
BHVN Biohaven Ltd. Buy 4.17% -1.69%
SIGA SIGA Technologies, Inc. Buy 4.73% -2.97%
SENS Senseonics Holdings, Inc. Buy 4.2% -1.77%
TGTX TG Therapeutics, Inc. Buy 4.77% 4.79%
The percentage of cash held in the portfolio is: 22.1%
New Assets Added
None
Assets Removed
Asset Action Perf %
NUTX Sell All 33.72%
ACRS Sell All -4.4%
Assets Rebalanced
None
2025-01-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
NUTX Nutex Health Inc. Buy 6.06% 26.44%
ACRS Aclaris Therapeutics, Inc. Buy 4.7% -2%
MD Pediatrix Medical Group, Inc. Buy 5.03% 4.86%
MDXG MiMedx Group, Inc. Buy 4.73% -1.25%
NVRO Nevro Corp. Buy 5.66% 18.16%
LGND Ligand Pharmaceuticals Incorporated Buy 5.1% 6.35%
AXSM Axsome Therapeutics, Inc. Buy 5.25% 9.54%
CERS Cerus Corporation Buy 5.57% 16.22%
DNLI Denali Therapeutics Inc. Buy 5.17% 7.86%
ATXS Astria Therapeutics, Inc. Buy 4.64% -3.21%
RGNX REGENXBIO Inc. Buy 4.94% 3.09%
ANIP ANI Pharmaceuticals, Inc. Buy 5.12% 6.84%
ORGO Organogenesis Holdings Inc. Buy 5.19% 12.31%
AGEN Agenus Inc. Buy 3.98% -6.01%
BHVN Biohaven Ltd. Buy 4.34% 2.31%
SIGA SIGA Technologies, Inc. Buy 4.84% -0.78%
SENS Senseonics Holdings, Inc. Buy 4.01% -6.19%
TGTX TG Therapeutics, Inc. Buy 4.55% 0%
The percentage of cash held in the portfolio is: 11.11%
New Assets Added
  • TGTX
Assets Removed
Asset Action Perf %
AXGN Sell All -1.75%
INSM Sell All 12.62%
VERU Sell All -24.39%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings